What Researchers Did
Researchers studied how combining carboplatin chemotherapy with hyperbaric oxygen therapy affected six Japanese patients with malignant brain tumours.
What They Found
They found that carboplatin stayed in the body significantly longer in patients who responded well to treatment (mean residence time of 4.3 +/- 1.7 hours) compared to those whose disease progressed (2.4 +/- 0.1 hours). This difference was statistically significant (p < 0.05). This suggests that hyperbaric oxygen therapy, given at 0.2 MPa for 60 minutes, might extend how long carboplatin is available to fight brain tumours.
What This Means for Canadian Patients
For Canadian patients with malignant gliomas, this study suggests that hyperbaric oxygen therapy could potentially enhance the effectiveness of carboplatin chemotherapy by increasing its time in the body. If further research confirms these findings, it could offer a new strategy to improve treatment outcomes for these challenging brain cancers.
Canadian Relevance
This study was conducted in Japan and does not involve Canadian authors or institutions. Malignant gliomas are not a Health Canada-recognised indication for HBOT.
Study Limitations
This study involved a very small number of patients (six), limiting the generalizability of its findings.